›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:InVisionFirst®-Lung
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
NeoGenomicsType:
Laboratory Developed Test
Related tests:
InVisionFirst®-Lung, a ctDNA NGS liquid biopsy is a 37-gene next-generation sequencing assay performed on cell-free circulating tumor DNA in peripheral blood to detect oncogenic driver mutations and therapy targets in non-small cell lung cancer (NSCLC). This assay demonstrated 98% concordance with tissue in clinical validation. Testing is performed by Inivata.
Cancer:
Non Small Cell Lung Cancer
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase)
See More ...
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), STK11 (Serine/threonine kinase 11)
Method:
Circulating Tumor DNA (ctDNA)
Confirmatory trial(s)
Confirmatory trial(s)
